Welcome to our dedicated page for Anteris Technologies Global SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
Anteris Technologies Global Corp. (AVR) approved significant equity awards for senior executives and a key employee, primarily in the form of nonqualified stock options and performance-based restricted stock units, with most grants contingent on stockholder approval.
Wayne Paterson was approved for 1,200,000 stock options and 800,000 PSUs, and David St Denis for 414,000 stock options and 485,000 PSUs, all granted on September 13, 2026 with 10-year terms for the options and multi-year vesting. The PSU awards vest over a five-year period based on achieving stock price hurdles of $21.50, $41.00, and $61.50, with accelerated vesting on death, disability, or certain change-in-control events. Separately, Matthew McDonnell received a nonqualified option grant over CHESS Depositary Interests with a target value of $500,000, vesting over three years and subject to similar change-in-control and forfeiture conditions.
Anteris Technologies Global Corp. (AVR) reported that its Chief Financial Officer, Moen Brent, received a grant of 90,274 employee stock options on September 11, 2026. The options have an exercise price of $8.35 per share, expire on September 11, 2036, and vest in approximately equal installments on September 11, 2027, 2028, and 2029, subject to continued service.
Anteris Technologies Global Corp. (AVR) had its Chief Financial Officer, Moen Brent, file an initial Form 3 reporting his status as an officer. The filing lists no reportable transactions, derivative positions, or equity holdings, serving as a baseline disclosure of insider ownership for future filings.
Anteris Technologies Global Corp. (AVR) filed a prospectus supplement to its Form S-1 registration statement covering up to 9,103,796 shares of common stock that may be sold from time to time by selling stockholders. The supplement incorporates a recent Current Report on Form 8-K.
The 8-K reports that, on September 4, 2026, Anteris appointed Brent Moen as Chief Financial Officer, effective September 11, 2026, under an employment agreement providing a $475,000 annual base salary, a target bonus of up to 50% of base salary (prorated for 2026), and eligibility for long-term equity incentives, including a 2026 stock option award with a target grant date value of $500,000 that vests in three equal annual installments and has a 10-year term. If terminated without cause, he is eligible for nine months of base salary continuation and up to nine months of COBRA premium reimbursement, subject to a release. Former CFO Matthew McDonnell will transition to Head of Australia, continuing under his existing compensation and benefit arrangements.
Anteris Technologies Global Corp. (AVR) appointed Brent Moen as Chief Financial Officer, effective September 11, 2026, succeeding Matthew McDonnell, who will become Head of Australia and remain an employee under his current compensation and benefits.
Moen’s employment agreement provides an annual base salary of $475,000, a target annual bonus opportunity of up to 50% of base salary (prorated for 2026), and eligibility for long-term incentives and other executive benefit plans. For 2026, the board’s compensation committee approved a long-term incentive award with a target value of $500,000 in nonqualified stock options under the company’s Equity Incentive Plan, with an exercise price equal to the fair market value on the September 11, 2026 grant date. These options vest in three substantially equal annual installments and have a 10-year term.
On a termination by the company without cause, Moen is eligible for nine months of base salary continuation and up to nine months of COBRA premium reimbursement, subject to signing a release. His agreement also includes confidentiality, non-solicitation, invention assignment, and a standard company indemnification agreement.
Anteris Technologies Global Corp. (AVR) reports that Australian investment manager L1 Capital Pty Ltd has filed an amended Schedule 13G showing beneficial ownership of 11,496,345 common stock equivalents, representing 11.64% of the company’s common stock on a partially diluted basis including specified warrants.
The position consists of 4,803,541 shares of common stock, 5,359,470 CHESS Depository Instruments (CDIs), and 1,333,334 CDI warrants that are exercisable within 60 days at AUD 11.50 per CDI, all held through L1-managed funds with sole voting and dispositive power reported.
Anteris Technologies Global Corp. (AVR) had insider activity reported by major shareholder L1 Capital Pty Ltd. On 2026-08-28, entities controlled and managed by L1 Capital sold 7,800 shares of Common Stock at $8.83 per share in an indirect transaction, leaving 4,803,541 Common shares held indirectly. L1 Capital-related funds also hold 5,359,470 CHESS Depository Interests, each representing one underlying common share, and 1,333,334 CHESS Depository Interest Warrants with an exercise price of AUD 11.50 expiring on 2030-10-30, all reported as indirect holdings.
Anteris Technologies Global Corp. (AVR) reported that Chief Operating Officer David St Denis exercised 60,000 stock options for Common Stock on August 19, 2026 at an exercise price of $5.65 per share. The corresponding option award, granted on September 23, 2021, now shows 0 options remaining. On the same date, 45,072 Common Shares were delivered or withheld at $9.58 per share to pay the exercise price or related tax liability. The filing indicates these transactions were not made under a Rule 10b5-1 trading plan.
Nantahala Capital Management, LLC and related individuals report beneficial ownership of Anteris Technologies Global Corp. common stock. As of June 30, 2026, Nantahala, together with Wilmot B. Harkey and Daniel Mack, may be deemed to beneficially own 3,995,579 shares, representing 4.08% of the outstanding common stock.
The position includes 612,244 shares that may be acquired within sixty days through the exercise of convertible securities. All 3,995,579 shares are reported with shared voting and shared dispositive power, and no shares are reported with sole voting or sole dispositive power. The filing states ownership of five percent or less of the class.
Anteris Technologies Global Corp. is a development-stage cardiac device company advancing its DurAVR® transcatheter heart valve system through a global pivotal Trial intended to support FDA Premarket Approval and CE Mark. Recruitment is underway in Europe, the United States and France, supported by IDE clearance and U.S. Medicare reimbursement eligibility for the study.
For the three months ended June 30, 2026, net sales were $1.0 million, up from $0.6 million, largely from regenerative tissue products, while the company recorded a net loss attributable to stockholders of $29.1 million. For the first half of 2026, net sales were $1.5 million and the net loss was $52.1 million, driven mainly by R&D expenses of $40.8 million and selling, general and administrative expenses of $15.3 million as clinical, manufacturing and headcount investments increased.
Liquidity strengthened significantly: cash, cash equivalents and restricted cash totaled $260.9 million at June 30, 2026, following a January 2026 public offering and a strategic private placement to Medtronic generating approximately $320.0 million in gross proceeds, plus an established $250.0 million at-the-market equity program. Management believes existing cash resources will fund operations for at least 12 months, though recurring losses are expected to continue. Previously identified material weaknesses in internal control over financial reporting remain under remediation and caused disclosure controls and procedures to be deemed not effective as of June 30, 2026.